Robinson Pharma Develops New Softgel Method

SANTA ANA ,Calif.Robinson Pharma Inc. developed ART Caps, a patent-pending (application # 13/116,943) composition and method for the manufacture of enteric softgels that creates a new gel polymer structure, which resists stomach acid to facilitate the delayed release of the capsules active ingredients. Robinson Pharma said it can now use this technology to develop enteric softgels that feature novel acid resistant technology, enhanced moisture tolerance and greater shell robustness for the dietary supplement industry.

ARTcaps is a diversified technology that can produce clear or colored softgels that comply with the USP standard for enteric release and can be manufactured in Robinson Pharmas continuous drying production lines. The new gel polymer structure is applicable to a wide variety of fill materials and does not require additional processing after encapsulation. Robinson Pharma said the ARTcaps technology has demonstrated superior resistance to moisture over other enteric processes and produces a gelatin shell that is significantly more resistant to both mechanical and acid-induced premature rupture.

Initial plans for ARTcaps product applications will be for nutritional products, specifically high-strength omega 3 concentrates. Robinson Pharma Inc.s Omega-3 30% Fish Oil Softgels were recently verified by USP Dietary Supplement Verification Program (DSVP), allowing the company to use the USP Verified Mark on the product label.